RxElite Inc. Fourth Quarter and Year-End 2007 Earnings Release and Conference Call Notice

Wednesday, March 19, 2008 General News J E 4
MERIDIAN, Idaho, March 18 RxElite, Inc.(OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer ofspecialty generic prescription drug products, today announced it will discussits 2007 year-end financial results in a conference call on Thursday, March20, 2008, at 11:00 a.m. EDT.

The Company will release its 2007 year-end financial results after themarket closes on Wednesday, March 19, 2008. Hosting the call will be RxEliteCEO Jonathan Houssian, COO Earl E. Sullivan, and VP of Finance Shannon M.Stith.

Conference Call

To participate in the conference call, callers from the USA and Canadaplease dial 1(800) 219-6110, all other international calls please dial(303) 262-2130. All callers should dial in five to ten minutes prior to theconference call time.

Audio Stream and Webcast

You may also participate via live audio stream by logging on to A rebroadcast of the audio streamwill be available using the same web link for 90 days after the initialbroadcast.

About RxElite, Inc.

RxElite, Inc. develops, manufactures and markets generic prescription drugproducts in specialty generic markets. These markets include products in theareas of anesthesia, sterile liquid dose drugs (including respiratoryinhalation drugs, ophthalmics and injectable drugs) and transdermal patchproducts.

Safe Harbor Statement

This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 involving known andunknown risks, delays, and uncertainties that may cause our actual results orperformance to differ materially from those expressed or implied by theseforward-looking statements. These risks, delays, and uncertainties include,but are not limited to: risks associated with the uncertainty of futurefinancial results, our reliance on our sole supplier, the limiteddiversification of our product offerings, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission. The Company undertakes no obligation toupdate any forward-looking statements.For More Information: Corporate Information Ph: (208) 288-5550 Toll Free: (800) 414-1901 Fax: (208) 288-1191 Investor Relations Craig Bird, 215-885-4981 Segue Ventures LLC

SOURCE RxElite, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Quixtar Files Suit Against MonaVie To Protect Cons...
Chindex International, Inc. Announces Three-For-Tw...